Zobrazeno 1 - 10
of 176
pro vyhledávání: '"Jose Nativi"'
Autor:
Nerea Mora-Ayestaran, MD, Angela Dispenzieri, MD, Arnt V. Kristen, MD, Mathew S. Maurer, MD, Igor Diemberger, MD, Brian M. Drachman, MD, Martha Grogan, MD, Pritam Gupta, PhD, Oliver Glass, PhD, Leslie Amass, PhD, Pablo Garcia-Pavia, MD, PhD, Michele Emdin, Mazen Hanna, Olga Azevedo, Calogero Lino Cirami, Jose Gonzalez Costello, David Slosky, Henning Moelgaard, Jose Nativi Nicolau, Scott Hummel, Eun-Seok Jeon, Nowell Fine, Srinivas Murali, Edward Miller, Sanjiv Shah, Ronald Witteles, Marcia Waddington-Cruz, Daniel Lenihan, Yoshiki Sekijima, Johan Van Cleemput, Edileide de Barros Correia, Eve Cariou, Dianna Quan, Miriam Freimer, David Steidley, Anna Hüsing-Kabar, Violaine Plante-Bordeneuve, Hans Nienhuis, Jonas Wixner, Jeffrey Ralph, Hector Ventura, Sasa Zivkovic, Diego Delgado, Roberto Fernandéz Torrón, Stephen Gottlieb, William Cotts, Jose Tallaj, Robert Brunkhorst, Michael Polydefkis, Christopher Mueller, Carsten Tschoepe, Juan Gonzalez Moreno, Nitasha Sarswat, Jin Luo, James Tauras, Alberta Warner
Publikováno v:
JACC: Advances, Vol 3, Iss 8, Pp 101086- (2024)
Background: Wild-type transthyretin amyloidosis (ATTRwt amyloidosis) is primarily diagnosed in elderly men but diagnoses in younger patients and women have recently increased. Objectives: The purpose of this study was to examine age- and sex-related
Externí odkaz:
https://doaj.org/article/dc542adf430b4e7fb29d0bce4d17c600
Autor:
Jose Nativi-Nicolau, Ali Yilmaz, Noel Dasgupta, Richard Macey, James Cochrane, Judith Peatman, Catherine Summers, Jennifer Luth, Ronald Zolty
Publikováno v:
Journal of Comparative Effectiveness Research, Vol 13, Iss 7 (2024)
Aim: The six-minute walk test (6MWT) is a common measure of functional capacity in patients with heart failure (HF). Primary clinical study end points in cardiomyopathy (CM) trials, including transthyretin-mediated amyloidosis with CM (ATTR-CM), are
Externí odkaz:
https://doaj.org/article/0f9a26f8ed0f478b991cca3b3481423d
Autor:
Shriya Sharma, Jose Ruiz, Pankaj Garg, Juan Leoni, Parag Patel, Jose Nativi, Melissa Lyle, Rohan Goswami
Publikováno v:
JHLT Open, Vol 4, Iss , Pp 100051- (2024)
Background: Left ventricular non-compaction syndrome (LVNC) is an uncommon congenital disease characterized by prominent trabeculations and deep inter-trabecular recesses of the left ventricle wall. We present the first reported case of Impella 5.5 u
Externí odkaz:
https://doaj.org/article/c8116087f50e4772b2f0cfa3503c6341
Autor:
Ji-Min Jang, Tambi Jarmi, Basar Sareyyupoglu, Jose Nativi, Parag C. Patel, Juan C. Leoni, Kevin Landolfo, Si Pham, Daniel S. Yip, Rohan M. Goswami
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-9 (2023)
Abstract Impaired kidney function is often associated with acute decompensation of chronic heart failure and portends a poor prognosis. Unfortunately, current data have demonstrated worse survival in patients with acute kidney injury than in patients
Externí odkaz:
https://doaj.org/article/268f3a537ab34c92bc259cb5d5204695
Autor:
Jose Nativi‐Nicolau, Daniel P. Judge, James E. Hoffman, Balarama Gundapaneni, Denis Keohane, Marla B. Sultan, Martha Grogan
Publikováno v:
ESC Heart Failure, Vol 8, Iss 5, Pp 3875-3884 (2021)
Abstract Aims Transthyretin amyloid cardiomyopathy (ATTR‐CM) is a progressive, fatal disorder that remains underdiagnosed. The Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT) was the first large clinical trial to include both
Externí odkaz:
https://doaj.org/article/ed6c657b00124d18852e9f82fb9d24d3
Autor:
David Adams, Vincent Algalarrondo, Michael Polydefkis, Nitasha Sarswat, Michel S. Slama, Jose Nativi-Nicolau
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 16, Iss 1, Pp 1-17 (2021)
Abstract Background Hereditary transthyretin-mediated amyloidosis, also known as ATTRv amyloidosis (v for variant), is a rare, autosomal dominant, fatal disease, in which systemic amyloid progressively impairs multiple organs, leading to disability a
Externí odkaz:
https://doaj.org/article/bb662c9812aa4769aea875c173ecb963
Autor:
Thomas H. Brannagan, Michaela Auer-Grumbach, John L. Berk, Chiara Briani, Vera Bril, Teresa Coelho, Thibaud Damy, Angela Dispenzieri, Brian M. Drachman, Nowell Fine, Hanna K. Gaggin, Morie Gertz, Julian D. Gillmore, Esther Gonzalez, Mazen Hanna, David R. Hurwitz, Sami L. Khella, Mathew S. Maurer, Jose Nativi-Nicolau, Kemi Olugemo, Luis F. Quintana, Andrew M. Rosen, Hartmut H. Schmidt, Jacqueline Shehata, Marcia Waddington-Cruz, Carol Whelan, Frederick L. Ruberg
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 16, Iss 1, Pp 1-13 (2021)
Abstract Background The global spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causing the ongoing coronavirus disease 2019 (COVID-19) pandemic has raised serious concern for patients with chronic disease. A correlati
Externí odkaz:
https://doaj.org/article/b9e4c37d2b9b46ff846198a89fb03767
Autor:
Morie Gertz, David Adams, Yukio Ando, João Melo Beirão, Sabahat Bokhari, Teresa Coelho, Raymond L. Comenzo, Thibaud Damy, Sharmila Dorbala, Brian M. Drachman, Marianna Fontana, Julian D. Gillmore, Martha Grogan, Philip N. Hawkins, Isabelle Lousada, Arnt V. Kristen, Frederick L. Ruberg, Ole B. Suhr, Mathew S. Maurer, Jose Nativi-Nicolau, Candida Cristina Quarta, Claudio Rapezzi, Ronald Witteles, Giampaolo Merlini
Publikováno v:
BMC Family Practice, Vol 21, Iss 1, Pp 1-12 (2020)
Abstract Background Transthyretin amyloidosis (also known as ATTR amyloidosis) is a systemic, life-threatening disease characterized by transthyretin (TTR) fibril deposition in organs and tissue. A definitive diagnosis of ATTR amyloidosis is often a
Externí odkaz:
https://doaj.org/article/78acd23bfad24bcdb52811fe1e3f573a
Autor:
Jose Nativi-Nicolau, Nitasha Sarswat, Johana Fajardo, Muriel Finkel, Younos Abdulsattar, Adam Castaño, Lori Klein, Alexandra Haddad-Angulo
Publikováno v:
Clinical Medicine Insights: Cardiology, Vol 15 (2021)
Background: Because transthyretin amyloid cardiomyopathy (ATTR-CM) poses unique diagnostic and therapeutic challenges, referral of patients with known or suspected disease to specialized amyloidosis centers is recommended. These centers have develope
Externí odkaz:
https://doaj.org/article/d8adbbac31b34ec2851ef9883e6b408d
Autor:
Peter Wohlfahrt, Susan L. Zickmund, Stacey Slager, Larry A. Allen, Jose Nativi Nicolau, Abdallah G. Kfoury, G. Michael Felker, Jorge Conte, Kelsey Flint, Adam D. DeVore, Craig H. Selzman, Rachel Hess, John A. Spertus, Josef Stehlik
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 9, Iss 2 (2020)
Background Patient‐reported outcomes (PROs) objectively measure health‐related quality of life and provide prognostic information. Advances in technology now allow for rapid, patient‐friendly PRO assessment and scoring, yet the adoption of PROs
Externí odkaz:
https://doaj.org/article/bdf05461ea874afa975ada8d8ac86164